Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  CAS  PubMed  Google Scholar 

Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73.

Article  CAS  PubMed  Google Scholar 

El-Serag HB, Lenhard Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

Article  CAS  PubMed  Google Scholar 

Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281–91.

Article  PubMed  PubMed Central  Google Scholar 

Furusawa A, Naganuma A, Suzuki Y, et al. Two cases of rapid progression of esophageal varices after atezolizumab–bevacizumab treatment for hepatocellular carcinoma. Clin J Gastroenterol. 2022;15:451–9.

Article  PubMed  Google Scholar 

Suzuki H, Iwamoto H, Shimose S, et al. Case report: exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: a case series and literature review. Front Oncol. 2022;12:948293.

Article  PubMed  PubMed Central  Google Scholar 

Tsuruoka M, Inoue J, Ouchi K, et al. Duodenal variceal rupture during atezolizumab and bevacizumab treatment for hepatocellular carcinoma. Intern Med. 2023;62:1467–72.

Article  PubMed  Google Scholar 

Ha Y, Kim JH, Cheon J, et al. Risk of variceal bleeding in patients with advanced hepatocellular carcinoma receiving Atezolizumab/Bevacizumab. Clin Gastroenterol Hepatol. 2023;21:2421–3.

Article  PubMed  Google Scholar 

de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.

Article  PubMed  Google Scholar 

Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology. 2017;65:310–35.

Article  PubMed  Google Scholar 

Simon-Talero M, Roccarina D, Martínez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018;154:1694–705.

Article  PubMed  Google Scholar 

Nardelli S, Riggio O, Gioia S, et al. Spontaneous porto-systemic shunts in liver cirrhosis: clinical and therapeutical aspects. World J Gastroenterol. 2020;26:1726–32.

Article  PubMed  PubMed Central  Google Scholar 

Ohnishi K, Sato S, Saito M, et al. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol. 1986;81:450–5.

CAS  PubMed  Google Scholar 

Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020. https://doi.org/10.1016/j.ctrv.2020.102017.

Article  PubMed  Google Scholar 

Roviello G, Bachelot T, Hudis CA, et al. The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials. Eur J Cancer. 2017;75:245–58.

Article  CAS  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22.

Article  CAS  PubMed  Google Scholar 

Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Funyu J, Mochida S, Inao M, et al. VEGF can act as vascular permeability factor in the hepatic sinusoids through upregulation of porosity of endothelial cells. Biochem Biophys Res Commun. 2001;280:481–5.

Article  CAS  PubMed  Google Scholar 

DeLeve LD, Wang X, Hu L, et al. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol. 2004;287:757–63.

Article  Google Scholar 

Moreau R. VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol. 2005;43:6–8.

Article  CAS  PubMed  Google Scholar 

Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328–35.

Article  CAS  PubMed  Google Scholar 

Sugiyama T, Mizuno M, Aoki Y, et al. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single agent bevacizumab in Japanese patients with advanced cervical cancer. Jpn J Clin Oncol. 2017;47:39–46.

Article  PubMed  PubMed Central  Google Scholar 

Avastin prescribing information. http:// www. gene. com/ gene/ products/ information/ pdf/ avastin-prescribing. pdf. Accessed 10 Jan 2022.

Ehrlich HP, Hunt TK. Effects of cortisone and vitamin A on wound healing. AnnSurg. 1968;167:324–8.

CAS  Google Scholar 

Goforth P, Gudas CJ. Effects of steroids on wound healing: a review of the literature. J Foot Surg. 1980;19:22–8.

CAS  PubMed  Google Scholar 

Oxlund H, Fogdestam I, Viidik A. The influence of cortisol on wound healing of the skin and distant connective tissue response. Surg Gynecol Obstet. 1979;148:876–80.

CAS  PubMed  Google Scholar 

Wang AS, Armstrong AW, Armstrong EJ. Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg. 2013;206:410–7.

Article  CAS  PubMed  Google Scholar 

Tada F, Hiraoka A, Tada T, et al. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices. J Gastroenterol. 2023;58:1134–43.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu C, Rimassa L, Sun HC, et al. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021. https://doi.org/10.1177/17588359211031141.

Article  PubMed  PubMed Central  Google Scholar 

Honma Y, Shibata M, Gohda T, et al. Rapid progression of liver fibrosis induced by acute liver injury due to immune-related adverse events of atezolizumab. Intern Med. 2021;60:1847–53.

Article  PubMed  PubMed Central  Google Scholar 

Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019. https://doi.org/10.1155/2019/6391712.

Article  PubMed  PubMed Central  Google Scholar 

De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–90.

Article  PubMed  Google Scholar 

Fujiwara K, Kondo T, Fujimoto K, et al. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. J Gastroenterol. 2024;59:515–25.